Philip Morris International Inc. vs Zoetis Inc — how do they compare? Philip Morris International Inc. trades at $195 (market cap $293.07B), while Zoetis Inc trades at $74.43 (market cap $31.59B). The key difference: Philip Morris International Inc. is far larger — about 9.3× Zoetis Inc's market cap, and Philip Morris International Inc. pays the higher dividend (3.13%). Which is the better fit depends on your goals.
| PM | ZTS | |
|---|---|---|
Market Cap | $293.07B | $31.59B |
Sector | Consumer Staples | Health |
52-Week High | $192.98 | $156.76 |
52-Week Low | $144.33 | $71.91 |
Enterprise Value | $339.57B | $38.89B |
Dividend Yield | 3.13% | 2.81% |
Signals from Pluang's Aura AI — not financial advice
Philip Morris International (PM) trades at $194.30, up 0.82% today, with strong analyst support (68% buy ratings) and a consensus price target of $194. The stock shows bullish technical momentum above key support levels, supported by robust fundamentals including 2025 revenue of $40.65B and net income of $11.35B. Recent news highlights include a $500M impairment charge and updated 2026 guidance, while the IQOS brand gained recognition as a top global brand.
PM offers stable dividend income and growth potential, but faces headwinds from cost pressures, currency volatility, and regulatory risks in tobacco markets. The current valuation at 26.47 P/E appears reasonable given earnings consistency, though investors should monitor margin trends and illicit market impacts in Europe. Near-term price action hinges on Q2 2026 earnings versus the $2.04 EPS estimate.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →